Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038002 (splenomegaly)
 9,873 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Endoscopic variceal ligation combined with partial splenic embolization (EVL-PSE) was performed in a group of 13 patients with esophageal variceal bleeding and hypersplenism due to portal hypertension from January 1997 to March 1998. PSE was performed one to two weeks before or one week after initial EVL, and a range of 30% to 60% of the splenic parenchyma was embolized. Repeated EVL was performed at two week intervals until the varices were eradicated. Active bleeding in the nine patients was successfully controlled and all the varices of the 13 patients were eradicated after EVL-PSE. Eradication of the varices required two to five(mean 3.1) EVL sessions, follow-up ranging from 2 to 16 months(mean 6.9 months). In all but one case, no rebleeding occurred. All patients after PSE showed a good response on peripheral blood cell count and reduction of splenomegaly. No major complication or death related to the combination therapy was observed. Preliminary results in this study show that this combination therapy may result in more rapid eradication of the varices and reduce rebleeding after endoscopic variceal ligation. However, more data and studies may be necessary for further evaluation.
 ...
PMID:[Endoscopic variceal ligation combined with partial splenic embolization: preliminary clinical results]. 1080 68

Non-cirrhotic portal hypertension (NCPH) comprises diseases having an increase in portal pressure (PP) due to intraheptic or prehepatic lesions, in the absence of cirrhosis. The lesions are generally vascular, either in the portal vein, its branches or in the perisinusoidal area. Because the wedged hepatic venous pressure is near normal, measurement of intravariceal or intrasplenic pressure is needed to assess PP. The majority of diseases included in the category of NCPH are well-characterized disease entities where portal hypertension (PHT) is a late manifestation and, hence, these are not discussed. Two diseases that present only with features of PHT and are common in developing countries are non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal vein obstruction (EHPVO). Non-cirrhotic portal fibrosis is a syndrome of obscure etiology, characterized by 'obliterative portovenopathy' leading to PHT, massive splenomegaly and well-tolerated episodes of variceal bleeding in young adults from low socioeconomic backgrounds, having near normal hepatic functions. In some parts of the world, NCPF is called idiopathic portal hypertension (IPH) or 'hepatoportal sclerosis'. Because 85-95% of patients with NCPF and EHPVO present with variceal bleeding, treatment involves management with endoscopic sclerotherapy (EST) or variceal ligation (EVL). These therapies are effective in approximately 90-95% of patients. Gastric varices are another common cause of upper gastrointestinal bleeding in these patients and these can be managed with cyanoacrylate glue injection or surgery. Other indications for surgery include failure of EST/EVL, and symptomatic hypersplenism. The prognosis of patients with NCPF is good and 5 years survival in patients in whom variceal bleeding can be controlled has been reported to be approximately 95-100%.
 ...
PMID:Non-cirrhotic portal fibrosis: current concepts and management. 1208 24